MGMA

Belkins
The Medical Group Management Association (MGMA) helps create successful medical practices that deliver the highest-quality patient care. As the leading association for medical practice administrators and executives since 1926, MGMA helps improve members’ practices through exclusive member benefits, education, resources, news, information, advocacy, and networking opportunities, and produces some of the most credible and robust medical practice economic data and data solutions in the industry. Through its industry-leading ACMPE board certification and Fellowship programs, MGMA advances the profession of medical practice management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

news image

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More

RESEARCH

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

news image

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More

CELL AND GENE THERAPY

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

news image

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

news image

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More
news image

MEDICAL

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More
news image

RESEARCH

KINETA AND SAMSUNG BIOLOGICS ANNOUNCE ANTI-VISTA ANTIBODY IMMUNOTHERAPY DEVELOPMENT AND MANUFACTURING AGREEMENT

Samsung Biologics | July 21, 2021

Kineta, Inc., a clinical-stage biotech firm developing novel immunotherapies in oncology, has signed a strategic partnership agreement with Samsung Biologics, one of the world's top contract development and manufacturing companies (CDMO). To support the IND filing for KVA12.1, Kineta's new anti-VISTA antibody under development to treat solid tumors, Samsung Biologics will offer end-through-end CDMO services ranging from cell line development to cell line development clinical drug substan...

Read More
news image

CELL AND GENE THERAPY

ELEVATEBIO ANNOUNCES ISSUANCE OF U.S. PATENT PROVIDING PROTECTION FOR RNA-GUIDED NUCLEASES IDENTIFIED THROUGH ITS LIFE EDIT GENE EDITING PLATFORM

ElevateBio | November 25, 2021

ElevateBio, LLC, a cell and gene therapy technology company focused on powering transformative cell and gene therapies, announced that the United States Patent and Trademark Office has issued US Patent No. 11,162,114 with an anticipated expiry date of June 23, 2040, inclusive of 384 days of patent term adjustment . This patent, issued to LifeEDIT Therapeutics, Inc. is the first to provide composition and methods of use protection for various RNA-guided nucleases in Life Edit’s gene editing...

Read More
news image

CARDIFF ONCOLOGY ANNOUNCES $2.5 MILLION EQUITY INVESTMENT BY BIOTECH-FOCUSED FUNDAMENTAL INVESTOR ACORN BIOVENTURES

Cardiff Oncology | May 27, 2020

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced it has entered into a definitive securities purchase agreement with biotech-focused fundamental investor, Acorn Bioventures, LP, for $2.5 million.Under the agreement, Acorn Bioventures has agreed to purchas...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us